Market Cap
$12.5B
HALO
HALOZYME THERAPEUTICS, INC.
$109.86 ▲ +2.73%
Prev close $106.94Market cap$12.5B
ConsensusStrong Buy
12-mo target$99.56 (-9.4%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)32 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on HALO right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$7.0B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $16.3M sell
Insider Net $
-$16.3M
Social Sentiment
36° Cool
SEC Reports
6
Price chart 30d -0.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Insider
Daly James M was granted 1,775 shares
Director
Oct 1, 2026 Insider
Daly James M was granted 1,169 shares
Director
Oct 1, 2026 Insider
Posard Matthew L. sold 100 shares
Director @ $110.04 ($11.0K)
Oct 1, 2026 short_volume
Aug 20, 2026 SEC Short Volume: HALO — 62.2% short (0.7M / 1.2M)
Short: 718,268 | Exempt: 3,969 | TRF Vol: 1,155,638 | Short Ratio: 62.2% | Off-exchange volume (dark
CEO Helen Torley executed a large-scale option exercise and open-market sale program over Aug 17-19, 2026, selling a tot
CLUSTER — Impact 2/10
CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substantial cashless-settle
CLUSTER — Impact 2/10
Two HALO directors sold a combined $624K in open-market sales over a 3-day window, with the bulk ($548K) from Director K
CLUSTER — Impact 3/10
Jun 30, 2026 Inst.
LOS ANGELES CAPITAL MANAGEMENT — DOUBLED
1,938,035 shares ($151.7M)
Analyst ratings buy % +11.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 8, 2026 | Leerink Partners | UPGRADE | Outperform | 49% |
| Aug 7, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 7, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Aug 7, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Aug 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 10 | 3 | 0 | 0 | 81% | |
| Aug 1, 2026 | 2 | 10 | 4 | 0 | 0 | 75% | |
| Jul 1, 2026 | 2 | 9 | 4 | 1 | 0 | 69% | |
| Jun 1, 2026 | 2 | 9 | 4 | 1 | 0 | 69% | |
| May 1, 2026 | 2 | 9 | 3 | 1 | 0 | 73% | |
| Apr 1, 2026 | 2 | 9 | 3 | 1 | 0 | 73% | |
| Mar 1, 2026 | 2 | 9 | 3 | 1 | 0 | 73% | |
| Feb 1, 2026 | 2 | 9 | 3 | 1 | 0 | 73% |
Price targets
Where 9 covering analysts think HALO trades over the next 12 months.
$99.56 -9.4% upside Sell
Current$109.86 Low$70.00 Median$105.00 High$115.00 9 analysts
$70.00$115.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood -9.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
36°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 2.3/10.
NEUTRALCLUSTER2/10
CEO Helen Torley executed a large-scale option exercise and open-market sale program over Aug 17-19,
Aug 20, 2026
NEUTRALCLUSTER2/10
CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substan
Jul 10, 2026
NEUTRALCLUSTER3/10
Two HALO directors sold a combined $624K in open-market sales over a 3-day window, with the bulk ($5
Jul 3, 2026
NEUTRALCLUSTER2/10
CEO Helen Torley and a director sold a combined ~$214K in open-market shares on June 1, 2026, at ~$6
Jun 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: HALO — 62.2% short (0.7M / 1.2M)
Short: 718,268 | Exempt: 3,969 | TRF Vol: 1,155,638 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
other
Halozyme Announces Appointment of Jim Daly to its Board of Directors
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of
Sep 30, 2026
short_volume
Short Volume: HALO — 66.1% short (0.8M / 1.3M)
Short: 837,561 | Exempt: 190,749 | TRF Vol: 1,266,562 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: HALO — 69.8% short (0.6M / 0.8M)
Short: 579,843 | Exempt: 43,300 | TRF Vol: 830,219 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: HALO — 78.4% short (1.0M / 1.2M)
Short: 963,873 | Exempt: 24,710 | TRF Vol: 1,229,329 | Short Ratio: 78.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.29 | $2.15–$2.37 | 33.2% | +0.0% | 2↑ 1↓ | $0.5B | 6 |
| Next Q | $2.59 | $2.43–$2.67 | 1179.6% | +0.0% | 2↑ 1↓ | $0.5B | 6 |
| Current FY | $8.58 | $7.91–$8.90 | 106.7% | +0.0% | 2↑ 1↓ | $1.9B | 6 |
| Next FY | $10.39 | $10.00–$11.01 | 21.2% | +0.0% | 3↑ 1↓ | $2.1B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.291 | — |
| 7d ago | $2.291 | — |
| 30d ago | $2.291 | — |
| 60d ago | $2.189 | +0.102 |
| 90d ago | $2.189 | +0.102 |
Institutional ownership
Which big funds own HALO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $7.0B total value (90,102,157 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 13,271,095 | $1.0B | 14.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,351,312 | $418.8M | 6.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,299,008 | $414.8M | 5.9% | — |
| STATE STREET CORP | 5,179,434 | $405.4M | 5.8% | — |
| Invesco Ltd. | 3,177,997 | $248.7M | 3.5% | — |
| MORGAN STANLEY | 2,832,594 | $221.7M | 3.2% | — |
| Boston Partners | 2,773,568 | $216.8M | 3.1% | — |
| BANK OF AMERICA CORP /DE/ | 2,740,561 | $214.5M | 3.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,519,951 | $197.3M | 2.8% | — |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2,511,050 | $196.5M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 689,915 | 1,938,035 | +180.9% | $151.7M |
| UBS Group AG | ADD | 914,003 | 1,492,224 | +63.3% | $116.8M |
| NORGES BANK | NEW | — | 1,483,648 | — | $116.1M |
| GOLDMAN SACHS GROUP INC | ADD | 730,140 | 1,270,344 | +74.0% | $99.4M |
| Boston Trust Walden Corp | ADD | 679,563 | 1,083,062 | +59.4% | $84.8M |
| Assenagon Asset Management S.A. | DOUBLED | 21,322 | 997,643 | +4578.9% | $78.1M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 338,291 | 528,889 | +56.3% | $41.4M |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 355,099 | 517,158 | +45.6% | $40.5M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 731,811 | 479,611 | -34.5% | $37.5M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 528,031 | 356,472 | -32.5% | $27.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$16.3M — $0.00 bought, $16.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Daly James M | Director | AWARD | 1,775 | — | — |
| Oct 1, 2026 | Daly James M | Director | AWARD | 1,169 | — | — |
| Oct 1, 2026 | Posard Matthew L. | Director | SELL | 100 | $110.04 | $11.0K |
| Oct 1, 2026 | Posard Matthew L. | Director | SELL | 730 | $107.17 | $78.2K |
| Oct 1, 2026 | Posard Matthew L. | Director | SELL | 3,300 | $108.45 | $357.9K |
| Oct 1, 2026 | Posard Matthew L. | Director | SELL | 1,100 | $109.57 | $120.5K |
| Sep 16, 2026 | Posard Matthew L. | Director | SELL | 3,100 | $106.13 | $329.0K |
| Sep 16, 2026 | Posard Matthew L. | Director | SELL | 3,000 | $106.83 | $320.5K |
| Sep 16, 2026 | Posard Matthew L. | Director | SELL | 8,896 | $108.04 | $961.1K |
| Sep 16, 2026 | Posard Matthew L. | Director | SELL | 4,000 | $108.99 | $436.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HALO.
Shares short
15,154,414
Settlement Sep 15, 2026
Change vs prior
+1.8%
Semi-monthly cycle
Days to cover
11.6
At avg daily volume
Of shares outstanding
≈13.3%
Estimate — not % of float
All HALO filing & press-release reports (6)
- CLUSTER reportAug 20, 2026
- CLUSTER reportJul 10, 2026
- CLUSTER reportJul 3, 2026
- CLUSTER reportJun 4, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportMar 23, 2026